Drug Delivery and Translational Research最新文献_第10页

3D-Printed core-shell tablet for effective oral delivery of AT-MSC secretome in inflammatory bowel disease therapy. 用于炎症性肠病治疗的有效口服AT-MSC分泌组的3d打印核壳片。

IF 5.5 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-08 DOI: 10.1007/s13346-025-01932-7

Elena Munoz-Perez, Edorta Santos-Vizcaino, Alvaro Goyanes, Abdul W Basit, Rosa Maria Hernandez

{"title":"3D-Printed core-shell tablet for effective oral delivery of AT-MSC secretome in inflammatory bowel disease therapy.","authors":"Elena Munoz-Perez, Edorta Santos-Vizcaino, Alvaro Goyanes, Abdul W Basit, Rosa Maria Hernandez","doi":"10.1007/s13346-025-01932-7","DOIUrl":"https://doi.org/10.1007/s13346-025-01932-7","url":null,"abstract":"The complexity of inflammatory bowel disease (IBD) and its pharmacological management has driven research to explore novel treatment options for this condition. Among the emerging therapies, Mesenchymal Stromal Cells (MSCs) have proven to be effective, showing strong immunomodulatory properties. However, the efficiency of direct MSC administration has been questioned due to their short half-life and risk of rejection. As an alternative, MSCs secretome, containing the beneficial paracrine effectors of MSCs, is being explored as a promising cell-free therapeutic tool. However, the oral delivery of this secretome is complex and presents a significant technological challenge. Additionally, the personalization of secretome-based therapies is essential, as it is a costly treatment that requires dose customization for each patient. This study introduces a novel approach for the oral delivery of adipose-tissue derived MSC secretome (AT-S) using 3D-printed core-shell tablets. Remarkably, lyophilized secretome (LpAT-S) was used during the study to improve the manageability and stability of the secretome. The 3D printed system proved to be capable of protecting secretome proteins from gastric degradation, offering an unprecedented possibility for the oral administration of secretome therapies. Overall, this study shows that 3D printing offers a promising, patient-friendly solution for the oral administration of MSC secretome for the first time, aligning with precision medicine goals to provide tailored therapies for IBD.","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted oral delivery of microencapsulated TNF-α siRNA in an experimental model of colitis. 在结肠炎实验模型中靶向口服微胶囊化TNF-α siRNA。

IF 5.5 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-06 DOI: 10.1007/s13346-025-01936-3

Thomas Stalder, Brice Moulari, Raphaël Cornu, Jérôme Chatelain, Nathan Koenig, Ahmed Hassan, Claire Chretien, Romain Boidot, Corentin Richard, Yann Pellequer, Florian Jurin, Henri Pierre, Hélène Martin, Arnaud Béduneau

{"title":"Targeted oral delivery of microencapsulated TNF-α siRNA in an experimental model of colitis.","authors":"Thomas Stalder, Brice Moulari, Raphaël Cornu, Jérôme Chatelain, Nathan Koenig, Ahmed Hassan, Claire Chretien, Romain Boidot, Corentin Richard, Yann Pellequer, Florian Jurin, Henri Pierre, Hélène Martin, Arnaud Béduneau","doi":"10.1007/s13346-025-01936-3","DOIUrl":"https://doi.org/10.1007/s13346-025-01936-3","url":null,"abstract":"Inflammatory bowel diseases (IBD) affect millions of people worldwide. The use of anti-TNF-α for the treatment of moderate-to-severe IBD faces primary non-response, loss of response during treatment or intolerance issues. As an alternative, a strategy consisting of oral administration of TNF-α siRNA was evaluated in the present study for the local treatment of IBD. TNF-α siRNA entrapped in lipid nanoparticles (LNPs) was microencapsulated in gastroresistant alginate particles using an original process. The encapsulation yield of both siRNA and LNPs in microparticles (MPs) was at least 90%. Oral administration of MPs significantly reduced both clinical score and therapeutic index in a TNBS-induced colitis model in mice. Near complete removal of tissue damage, including edema, ulceration and necrosis, was observed in colon sections from treated mice. Reduced variation in gene sets involved in the global inflammatory response and the TNF-α/NF-κB signaling pathway was detected in the colon compared to untreated mice, demonstrating the anti-inflammatory activity of MPs. Finally, biodistribution studies showed the targeting of the inflamed colon by MPs and the colocalization of LNPs and MPs at the site of action. These MPs may represent a promising siRNA delivery platform for the oral treatment of IBD.","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer. 基因生物工程PD-L1靶向外泌体用于耐药三阴性乳腺癌的免疫治疗

IF 5.5 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-05 DOI: 10.1007/s13346-025-01920-x

Mounika Aare, Jassy Mary S Lazarte, Magesh Muthu, Arun K Rishi, Mandip Singh

{"title":"Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer.","authors":"Mounika Aare, Jassy Mary S Lazarte, Magesh Muthu, Arun K Rishi, Mandip Singh","doi":"10.1007/s13346-025-01920-x","DOIUrl":"https://doi.org/10.1007/s13346-025-01920-x","url":null,"abstract":"Immunotherapy has transformed cancer treatment by harnessing the immune system to target tumor cells, with PD-L1 inhibition emerging as a promising strategy. Exosomes, which naturally function as nanocarriers, offer significant potential for delivering therapeutic payloads, while genetic engineering allows for improved cargo specificity and efficacy. Here, for the first time, we genetically engineered exosomes to express anti-PD-L1 (PDL E) on their surface, enabling targeted drug delivery and immunotherapeutic activity. These engineered exosomes were then loaded with STAT3 siRNA (PDL ESi) and evaluated against doxorubicin-resistant MDA-MB-231 cells in combination with paclitaxel. Both in vitro and in vivo studies demonstrated a pronounced reduction in tumor burden (P < 0.001) and progression. Mechanistic investigations revealed that these exosomes activated apoptotic pathways, including the PI3K/AKT/mTOR axis, while inhibiting survival signals such as BCL-2, thereby enhancing tumor cell apoptosis. Notably, PD-L1 expression was downregulated in tandem with modulation of the STAT3/Nrf2 signaling axis, further augmenting the anti-tumor immune response. Toxicity studies in MCF-10 A cells showed that PDL ESi was well-tolerated, with no off-target effects. Imaging analyses in both 3D spheroids and tumor xenograft models confirmed the efficient tumor targeting of PDL E, demonstrating their time-dependent accumulation at the tumor site. Collectively, these findings highlight the promise of PD-L1-targeted, genetically engineered exosomes as a versatile platform for combination cancer therapy, providing a multifaceted strategy to overcome therapeutic resistance in TNBC.","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of the Orbit® subretinal delivery system (Orbit® SDS device) and prototypes in adult and juvenile canine eyes. Orbit®视网膜下输送系统（Orbit®SDS装置）和成人和青少年犬眼原型的评估。

IF 5.5 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-02 DOI: 10.1007/s13346-025-01929-2

Jennifer C Kwok, Alexa P Gray, Yu Sato, Svetlana Savina, Natalia Dolgova, Raghavi Sudharsan, Sanford L Boye, Shannon E Boye, Sam Reichenbacker, Tom Meyer, Kirsten Stoner Cummiskey, William A Beltran

引用次数: 0

Blended ƙ-carrageenan and xanthan gum hydrogel containing ketoprofen-loaded nanoemulsions: Design, characterization, and evaluation in an animal model of rheumatoid arthritis. 混合ƙ-carrageenan和黄原胶水凝胶含有酮洛芬负载纳米乳液：设计，表征和类风湿关节炎动物模型的评估。

IF 5.7 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-01 Epub Date: 2025-01-16 DOI: 10.1007/s13346-024-01786-5

Marcel Henrique Marcondes Sari, Verônica Ferrari Cervi, Vanessa Neuenschwander Custódio, Vinicius Costa Prado, Ketlyn Pereira da Motta, Cristiane Luchese, Ethel Antunes Wilhelm, Luana Mota Ferreira, Letícia Cruz

{"title":"Blended ƙ-carrageenan and xanthan gum hydrogel containing ketoprofen-loaded nanoemulsions: Design, characterization, and evaluation in an animal model of rheumatoid arthritis.","authors":"Marcel Henrique Marcondes Sari, Verônica Ferrari Cervi, Vanessa Neuenschwander Custódio, Vinicius Costa Prado, Ketlyn Pereira da Motta, Cristiane Luchese, Ethel Antunes Wilhelm, Luana Mota Ferreira, Letícia Cruz","doi":"10.1007/s13346-024-01786-5","DOIUrl":"10.1007/s13346-024-01786-5","url":null,"abstract":"This study reports the preparation of hydrogels (HG) made with xanthan gum (XG) and ƙ-carrageenan (KC) polysaccharides containing ketoprofen (KET)-loaded nanoemulsions (NK) and their evaluation in a rheumatoid arthritis (RA) model. The nano-based HGs exhibited nanometric-sized droplets (~ 100 nm), an acidic pH (5.10-6.83), drug content above 85%, a suitable spreadability factor, and pseudoplastic flow behavior. The most promising blend (HGCX 2:1) demonstrated sustained KET release, reaching 81.44 ± 6.11% after 5 h, and superior drug concentration in the skin layers (237.91 ± 41.0 µg/g). The formulation was selected due to its enhanced bioadhesiveness, with the HG-NK formulation showing the highest bioadhesion force and occlusion factor. RA was induced by complete Freund's adjuvant (CFA) intraplantar injection into the left hind paw of male and female Swiss mice. Treatments with HGs were applied to the animals' dorsal region for 7 days. Notably, HG-NK demonstrated remarkable efficacy, reversing mechanical sensitivity in male mice and significantly reducing thermal sensitivity in both genders. Moreover, HG-NK provided a significant reduction in paw edema (52-fold in males, 27-fold in females) and inflammatory markers, such as myeloperoxidase activity (32-fold in males, 14-fold in females) and lipid peroxidation (2.5-fold in males, twofold in females). The formulation also promoted greater permeation of KET across the skin. These findings underscore the significant reduction in inflammatory markers by the HG-NK formulation, highlighting its potent anti-inflammatory effects and potential as a promising therapeutic strategy for managing RA.","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":"2878-2903"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics. 一种新型ERCC1-XPF抑制剂的纳米递送用于结直肠癌对铂基化疗药物的靶向致敏。

IF 5.7 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-01 Epub Date: 2025-01-29 DOI: 10.1007/s13346-024-01782-9

Parnian Mehinrad, Ahmed Abdelfattah, Sams M A Sadat, Tanin Shafaati, Ahmed H Elmenoufy, David Jay, Frederick West, Michael Weinfeld, Afsaneh Lavasanifar

{"title":"Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics.","authors":"Parnian Mehinrad, Ahmed Abdelfattah, Sams M A Sadat, Tanin Shafaati, Ahmed H Elmenoufy, David Jay, Frederick West, Michael Weinfeld, Afsaneh Lavasanifar","doi":"10.1007/s13346-024-01782-9","DOIUrl":"10.1007/s13346-024-01782-9","url":null,"abstract":"In this study, a novel inhibitor of ERCC1/XPF heterodimerization, A4, was used as an inhibitor of repair for DNA damage by platinum-based chemotherapeutics. Nano-formulations of A4 were developed, using self-assembly of the following block copolymers: methoxy-poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) (PEO-b-PBCL), methoxy-poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL), or methoxy-poly(ethylene oxide)-block-poly (D, L, lactide) (PEO-b-PDLA 50-50). The nano-formulations were characterized for their average diameter, polydispersity, morphology, A4 encapsulation and in vitro release. The activity of A4 and its nano-formulation on the inhibition of ERCC1/XPF dimerization was investigated. The cytotoxicity of carboplatin and oxaliplatin in colorectal cancer (CRC) cell lines, without or with pre-treatment with A4 or its nanoparticle formulation was assessed by conducting colony forming as well as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays. Among the three nano-formulations of A4 under study, optimum properties were achieved with PEO-b-PBCL nanocarriers, showing an encapsulation efficiency of 83.1 ± 5.83%, loading content of 11.5 ± 0.37 w/w %, < 50% drug release within 24 hs, and an average diameter of < 150 nm. The chemo sensitizing effect of A4 and its nano-encapsulated counterparts were more noticeable when A4 was combined with carboplatin versus oxaliplatin. The results of cytotoxicity studies in HCT116 XPF-/- cells confirmed the specificity of A4 through an XPF-dependent mechanism in the sensitization of these cells to carboplatin at concentrations below 0.5 μM. The result of the study shows great potential for A4 and its PEO-b-PBCL nano-formulation in sensitization of CRC to platinum-based chemotherapeutics.","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":"2833-2847"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Simvastatin is delivered to the brain by high-strength intranasal cationic SMEDDS and nanoemulsions. 辛伐他汀通过高强度的鼻内阳离子SMEDDS和纳米乳液输送到大脑。

IF 5.7 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-01 Epub Date: 2025-01-02 DOI: 10.1007/s13346-024-01769-6

Francisco Gama, Sara Meirinho, Patrícia C Pires, Johann Tinoco, Maria Carolina Martins Gaspar, Graça Baltazar, Gilberto Alves, Adriana O Santos

{"title":"Simvastatin is delivered to the brain by high-strength intranasal cationic SMEDDS and nanoemulsions.","authors":"Francisco Gama, Sara Meirinho, Patrícia C Pires, Johann Tinoco, Maria Carolina Martins Gaspar, Graça Baltazar, Gilberto Alves, Adriana O Santos","doi":"10.1007/s13346-024-01769-6","DOIUrl":"10.1007/s13346-024-01769-6","url":null,"abstract":"The repurposing of statins as neuroprotective agents and/or anti-brain tumor drugs is limited by challenges in brain bioavailability and systemic off-target effects. Therefore, improved and targeted delivery of statins to the brain is necessary. This study aimed to develop a high-strength liquid formulation of the poorly soluble prodrug simvastatin for intranasal administration, as a strategy to achieve high brain concentrations of the prodrug and/or its active form, tenivastatin. Cationic simvastatin nanoemulsions (c-NE) and self-microemulsifying drug delivery systems (c-SMEDDS) were screened for composition, extensively characterized, and the viscosity of the nanoemulsion was further optimized. The optimized c-NE and c-SMEDDS formulations achieved high drug strengths, approximately 5.5% and 9% (w/w), respectively. They formed highly homogeneous aqueous dispersions (polydispersity index < 0.1) with small droplet sizes (< 120 nm and ~ 25 nm, respectively) and remained stable for at least four months under refrigeration. Neither the c-NE nor the c-SMEDDS induced hemolysis up to concentrations of 40 µg/mL and 450 µg/mL of simvastatin, respectively. The zero-shear viscosity of the c-NE was increased to 186 mPa·s by incorporating 0.25% (w/w) polyvinylpyrrolidone, which approached the viscosity of the c-SMEDDS (~ 126 mPa·s). Following intranasal administration of the optimized formulations to Wistar rats at a dose of 10 mg/kg, simvastatin levels in the brain reached 50 to 150 ng/g between 15 and 60 min post-administration. These findings indicate that the developed c-NE and c-SMEDDS formulations hold promise for simvastatin intranasal delivery and brain targeting, potentially paving the way for the realization of simvastatin's neuroprotective potential.","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":"2749-2764"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies. 通过开发纳米结构脂质载体提高大麻二酚口服生物利用度：体外和体内评估研究。

IF 5.7 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-01 Epub Date: 2024-12-30 DOI: 10.1007/s13346-024-01766-9

Iman E Taha, Mahmoud A ElSohly, Mohamed M Radwan, Rasha M Elkanayati, Amira Wanas, Poorva H Joshi, Eman A Ashour

{"title":"Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies.","authors":"Iman E Taha, Mahmoud A ElSohly, Mohamed M Radwan, Rasha M Elkanayati, Amira Wanas, Poorva H Joshi, Eman A Ashour","doi":"10.1007/s13346-024-01766-9","DOIUrl":"10.1007/s13346-024-01766-9","url":null,"abstract":"Cannabidiol (CBD) is a natural product isolated from the Cannabis sativa plant that was approved by the United States Food and Drug Administration (US FDA) for the treatment of resistant epilepsy. Despite its therapeutic potential, CBD's clinical application is limited by its poor aqueous solubility and low oral bioavailability. The primary aim of this research was to enhance the aqueous solubility and oral bioavailability of CBD by developing nanostructured lipid carriers (NLCs) using conventional hot homogenization method (CHH). In the current study, nine CBD NLC formulations were developed through CHH, of which, NLC5 emerged as the most promising formulation, exhibiting high CBD entrapment efficiency (99.23%), particle size of 207 nm, a polydispersity index of 0.19, and a zeta potential of -26 mV. Additionally, drug release testing for NLC5 showed a high CBD release rate of more than 90% within 15 min, indicating an enhancement of CBD dissolving rate compared to pure CBD. The in vivo pharmacokinetic study of NLC5 formulation showed 27% CBD oral bioavailability. Furthermore, Stability studies conducted at 4 °C and 25 °C on this formulation over three months, revealed consistent parameters, underscoring the robustness of the formulation. In conclusion, the successful formulation of CBD-loaded NLCs resulted in improved CBD release rate, enhanced oral bioavailability of CBD, and maintained stability, making it a promising approach for the effective delivery of CBD.","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":"2722-2732"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing hydrophilic drug incorporation into SEDDS using dry reverse micelles: a comparative study of preparation methods. 利用干燥反胶束优化亲水药物掺入SEDDS：制备方法的比较研究。

IF 5.7 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-01 Epub Date: 2025-01-16 DOI: 10.1007/s13346-024-01787-4

Sera Lindner, Fabrizio Ricci, Matthias Sandmeier, René Holm, Cecilia Bohns Michalowski, Nathaniel Washburn, Dajun Sun, Giustino Di Pretoro, Andreas Bernkop-Schnürch

{"title":"Optimizing hydrophilic drug incorporation into SEDDS using dry reverse micelles: a comparative study of preparation methods.","authors":"Sera Lindner, Fabrizio Ricci, Matthias Sandmeier, René Holm, Cecilia Bohns Michalowski, Nathaniel Washburn, Dajun Sun, Giustino Di Pretoro, Andreas Bernkop-Schnürch","doi":"10.1007/s13346-024-01787-4","DOIUrl":"10.1007/s13346-024-01787-4","url":null,"abstract":"Aim: It was the aim of this study to compare two different dry reverse micelle (RM) preparation methods for the incorporation of hydrophilic drugs into oral self-emulsifying drug delivery systems (SEDDS).Methods: Cationic ethacridine lactate, anionic fluorescein sodium salt and the antibiotic peptide bacitracin were solubilized in RM containing sodium docusate, soy phosphatidylcholine and sorbitan monooleate in highly lipophilic oils such as squalane. In the dry addition (DA) method, drugs were directly added to empty RM in their powder form. In the organic solvent-aided (OS) method, drugs were pre-dissolved in ethanol or 2-propanol, which were then evaporated to form loaded dry RM.Results: RM with sorbitan monooleate prepared via the DA method yielded up to 2.7-fold higher solubility only for bacitracin compared to the OS method. In contrast, OS-RM with sodium docusate and soy phosphatidylcholine exhibited significantly higher drug solubilities, achieving up to 109-fold, 44-fold and 97-fold increase for ethacridine, fluorescein and bacitracin, respectively. For all model drugs, the logDlipophilic phase/water was highest for RM comprising sorbitan monooleate, with a slight increase for OS-RM. This was consistent with the release profiles from SEDDS, showing an enhanced retention when loaded with OS-RM. While DA-RM showed no significant difference in cellular uptake, it was 1.6-fold higher in OS-RM loaded squalane-based SEDDS.Conclusion: The DA method is an easier approach for incorporating hydrophilic drugs into dry RM. However, the OS method presents a more promising alternative as it significantly enhanced the solubility and retention of these drugs in highly lipophilic formulations.","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":"2904-2923"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionizing Parkinson's treatment: Harnessing the potential of intranasal nanoemulsions for targeted therapy. 革新帕金森病治疗：利用鼻内纳米乳剂靶向治疗的潜力。

IF 5.7 3区医学

Drug Delivery and Translational Research Pub Date : 2025-08-01 Epub Date: 2025-01-08 DOI: 10.1007/s13346-024-01770-z

Gulshan Sharma, Karan Wadhwa, Shobhit Kumar, Govind Singh, Rakesh Pahwa

{"title":"Revolutionizing Parkinson's treatment: Harnessing the potential of intranasal nanoemulsions for targeted therapy.","authors":"Gulshan Sharma, Karan Wadhwa, Shobhit Kumar, Govind Singh, Rakesh Pahwa","doi":"10.1007/s13346-024-01770-z","DOIUrl":"10.1007/s13346-024-01770-z","url":null,"abstract":"Parkinson's disease (PD) is the most prominent and highly prevalent chronic neuro-degenerative disease generally recognized by classical motor symptoms which are linked with genetic mutation, Lewy bodies, and subsequently selective loss of nigrostriatal dopaminergic neurons. The blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier protect the central nervous system against toxins and are the most significant barriers to effective brain drug delivery in managing Parkinsonism. In recent years, intranasal delivery has attracted remarkable attention for brain targeting as the drug can be administered to the brain directly from the nose employing the trigeminal and olfactory pathways. For brain targeting through nasal delivery, several advanced and promising formulation techniques have been investigated globally. Nanoemulsions are regarded as an innovative carrier approach for PD, where these provide targeted administration and enhanced bioavailability of neurotherapeutics. This manuscript provides deeper insight into the pathophysiology of PD, various drug delivery strategies to overcome BBB, and the potential role of nanoemulsions via the intranasal route. Various research findings on the intranasal administration of nanoemulsions and their pivotal applications in the treatment of PD have also been embarked. The potential role of phytoconstituents and surface-modified nanoemulsions for the effective treatment of PD has also been reflected along with current challenges and future perspectives in this avenue.","PeriodicalId":11357,"journal":{"name":"Drug Delivery and Translational Research","volume":" ","pages":"2589-2607"},"PeriodicalIF":5.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0